For instance, the clinical trial NCT02638909, which aimed to investigate the potential of ceritinib in patients with advanced gastrointestinal malignancies (including colorectal adenocarcinoma, cholangiocarcinoma, pancreatic adenocarcinoma, hepatocellular adenocarcinoma, gastric adenocarcinoma, and esophageal adenocarcinoma) harboring ALK and ROS1 rearrangements, and who lacked alternative therapeutic options, was terminated due to inadequate enrollment [43]. This evidence concerns the gene ALK and gastric adenocarcinoma.